Digestive Diseases and Sciences

, Volume 39, Issue 11, pp 2446–2447 | Cite as

Response by Drs. Horsmans, Geubel, and Pauwels

  • Y. Horsmans
  • A. P. Geubel
  • S. Pauwels
Letters To The Editor


Public Health 


  1. 1.
    Pauwels S, Geubel AP, Dive C, Beckers C: Breath14CO2 after intravenous administration of aminopyrine in liver diseases. Dig Dis Sci 27:49–55, 1982Google Scholar
  2. 2.
    Miotti T, Bircher J, Preisig R: The 30-minute aminopyrine breath test: Optimization of sampling times after intravenous administration of14C-aminopyrine. Digestion 39:241–250, 1988Google Scholar
  3. 3.
    Beuers U, Jager F, Wahllander A, Ansari H, Kirsch CM: Prognostic value of the intravenous14C-aminopyrine breath test compared to the Child-Pugh score and serum bile acids in 84 cirrhotic patients. Digestion 50:212–218, 1991Google Scholar
  4. 4.
    Heymsfield SB, Waki M, Reinus J: Are patients with chronic liver disease hypermetabolic? Hepatology 11:502–505, 1990Google Scholar
  5. 5.
    Hepner GW, Vesell ES, Lipton A, Harvey HA, Wilkinson GR, Schenker S: Disposition of aminopyrine, antipyrine, diazepam, and indocyanine green in patients with liver disease or on anticonvulsivant drug therapy: diazepam breath test and correlations in drug elimination. J Lab Clin Med 90:440–456, 1977Google Scholar
  6. 6.
    Bircher J, Küpfer A, Gilakov I, Preisig R: Aminopyrine demethylation measured by breath analysis in cirrhosis. Clin Pharmacol Ther 20:484–492, 1976Google Scholar
  7. 7.
    Hepner GW, Vesell ES: Aminopyrine disposition: studies on breath, saliva, and urine of normal subjects and patients with liver disease. Clin Pharmacol Ther 20:654–660, 1976Google Scholar

Copyright information

© Plenum Publishing Corporation 1994

Authors and Affiliations

  • Y. Horsmans
    • 1
  • A. P. Geubel
    • 1
  • S. Pauwels
    • 1
  1. 1.Departments of Gastroenterology and Nuclear MedicineUniversity of Louvain Medical SchoolBrusselsBelgium

Personalised recommendations